Do you want to read an article? Please log in or register.
Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial
Gastrointestinal Cancer
Indications
Related content
Gastrointestinal Cancer
Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis
Lancet Oncol
Quik JSE, Vollebergh MA, Retèl VP, van der Sluis K, Koemans WJ, van der Kaaij RT, Voets MM, Luyer MDP, van Hellemond IEG, Wijnhoven BPL, Mostert B, van Hillegersberg R, Mohammad NH, van Etten B, de Groot DJ, Helminen O, Hedberg J, Cashin PH, Harbjerg JL, Veenhof AAFA, Hartemink KJ, Kodach LL, van der Noort V, van Sandick JW, PERISCOPE II consortium
doi: 10.1016/S1470-2045(26)00144-0
Leukemia
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial
Lancet Haematol
Nicolini FE, Etienne G, Huguet F, Charbonnier A, Roth-Guépin G, Escoffre-Barbe M, Dubruille V, Johnson-Ansah H, Rousselot P, Legros L, Parry A, Roy L, Coiteux V, Lenain P, Ianotto JC, Doublet C, Orvain C, Simonet-Boissard M, Chrétien ML, Penot A, Meunier M, Amé S, Hermet E, Quittet P, Lapusan S, Schwiertz V, Cayuela JM, Mauté C, Réa D, Morisset S, Mahon FX, Dulucq S
doi: 10.1016/S2352-3026(26)00043-8
Breast Cancer
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Lancet Oncol
Brunt AM, Cafferty FH, Kirby AM, Patel J, Sydenham MA, Haviland JS, Griffin S, Chivardi C, Fleming H, Coles CE, Bloomfield DJ, Chan C, Cleator S, Goodman A, Griffin CL, Kirwan CC, Nabi Z, Sawyer E, Somaiah N, Syndikus I, Venables K, Wheatley DA, Yarnold JR, Bliss JM
doi: 10.1016/S1470-2045(26)00076-8
Multiple Myeloma (MM)
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial
Lancet Haematol
Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J
doi: 10.1016/S2352-3026(25)00143-7
Leukemia
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
Lancet
Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Šimkovič M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG
doi: 10.1016/S0140-6736(26)01204-3
Breast Cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
Ann Oncol
Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF, DESTINY-Breast11 Trial Investigators
doi: 10.1016/j.annonc.2025.10.019
Multiple Myeloma (MM)
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
Lancet Haematol
Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV, DREAMM-7 trial study group
doi: 10.1016/S2352-3026(25)00163-2
Lung, Respiratory and Thoracic Cancer
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Lancet
Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W, SACHI Study Group
doi: 10.1016/S0140-6736(25)01811-2
Breast Cancer
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
Lancet Oncol
Seefat RL, Vliek SB, de Jong VMT, Balduzzi S, Mandjes IA, Retèl VP, Eekhout I, Delfos M, Schot M, Holtkamp MJ, van Rosmalen MM, Leeneman B, Blommestein H, Huitema ADR, Rosenberg EH, Nederlof PM, Chan TWS, van Rhenen A, Wondergem MJ, Schaap NPM, Snijders TJF, Van der Poel MWM, Plattel WJ, van Werkhoven E, van Tinteren H, Smidt ML, Wesseling J, Jonkers J, Rottenberg S, Vrancken Peeters MTFD, Voermans C, Maduro JH, Kroep JR, Schroder CP, Kuip EJM, Gonçalves A, Nuver J, Wymenga ANM, Bijlsma RM, van der Wall E, Konings IRHM, Tjan-Heijnen VCG, Jongen-Lavrencic M, Jager A, Linn SC
doi: 10.1016/S1470-2045(26)00131-2